L3VLUP
ProSign in

ALKS · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ALKSVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ALKS
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterALKSVRTX
Q3 202010 holders, $1.0bn31 holders, $21.9bn
Q4 202013 holders, $1.2bn30 holders, $18.4bn
Q1 202112 holders, $1.1bn31 holders, $15.4bn
Q2 202113 holders, $1.3bn30 holders, $12.7bn
Q3 202111 holders, $1.4bn35 holders, $10.1bn
Q4 20219 holders, $1.1bn28 holders, $12.4bn
Q1 202210 holders, $1.2bn23 holders, $16.1bn
Q2 202212 holders, $903m25 holders, $18.1bn
Q3 202210 holders, $547m22 holders, $18.4bn
Q4 202212 holders, $831m28 holders, $18.4bn
Q1 202312 holders, $708m26 holders, $21.4bn
Q2 202312 holders, $703m27 holders, $24.7bn
Q3 202312 holders, $778m33 holders, $24.3bn
Q4 20237 holders, $754m32 holders, $28.6bn
Q1 20248 holders, $927m31 holders, $29.8bn
Q2 20247 holders, $823m29 holders, $33.4bn
Q3 20248 holders, $955m27 holders, $33.5bn
Q4 20247 holders, $801m26 holders, $28.5bn
Q1 20259 holders, $813m21 holders, $35.4bn
Q2 20259 holders, $642m21 holders, $32.3bn
Q3 202510 holders, $703m22 holders, $25.9bn
Q4 20259 holders, $566m26 holders, $31.8bn
Q1 202610 holders, $436m25 holders, $31.8bn
Q2 20269 holders, $1.2bn26 holders, $34.6bn
ALKS

Alkermes PLC

Holders
7
Reported value
$754m
Buyers
4
Sellers
4

Breadth 0 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
32
Reported value
$28.6bn
Buyers
16
Sellers
16

Breadth 0 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2023

Among the 32 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ALKS (0)

None.

Only VRTX (25)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., Farallon Capital Management LLC, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Marshall Wace LLP, Maverick Capital Ltd, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, PDT Partners LLC, T. Rowe Price Associates Inc, Tudor Investment Corp, Two Sigma Investments LP, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →